Replies to post #178831 on Biotech Values

[DewDiligence]

…Botox reduces CGRP release—my guess is that's it's MOA in migraine…

How does this thesis square with the sensitivity of Botox efficacy in migraine to the precise placement of the multiple injection points?

[DewDiligence]

AVNR’s AVP-825 meets primary endpoint in phase-3b migraine study:

http://finance.yahoo.com/news/avanir-pharmaceuticals-announces-positive-outcome-080000787.html

The PDUFA date for AVP-825 is 11/26/14.

Seems like there's a lot of attention on migraine lately.